Eisai, Purdue To File Insomnia Drug Following Positive Head-To-Head
Executive Summary
Eisai and its partner Purdue are expected to file insomnia drug lemborexant with the US FDA within the next 12 months, following more positive data.
You may also be interested in...
Asia Deal Watch: Takeda Licenses Curadev STING Agonist To Further Its IO Ambitions
The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.
Keeping Track: FDA's Review Actions Carry On During Shutdown
The latest drug development news and highlights from our US FDA Performance Tracker.
Priority Review Voucher Crash: Spark's Sale To Jazz Lowest Price Since 2014
Only the first publicly disclosed sale of a priority review voucher was lower than what Jazz Pharmaceuticals paid Spark Therapeutics for its coupon.